Oramed Pharm AI Stock Analysis
Want to see ORMP full AI Analyst Report?
Oramed Pharm (ORMP) AI Stock Analysis
Oramed Pharm
(NASDAQ:ORMP)
Oramed scores in the below-average range. The dominant factor is weak operating fundamentals: no product revenue, ongoing operating losses and negative cash flow, with reported profits driven by accounting gains rather than the business. Offsetting this is an exceptionally strong, nearly debt-free balance sheet with $339.1 million of equity, which funds the pipeline and materially lowers financial risk. Technicals are soft, with the price below most key moving averages and negative MACD momentum. The sub-1x P/E is optically attractive but unreliable given the one-off nature of earnings, and there is no dividend. Routine shareholder approvals at the 2026 annual meeting add marginal governance stability. Ultimately, the investment case rests on clinical and pipeline execution rather than current operating performance.
Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $169.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 174.39K
- Price to Earnings (P/E)
- 1.1
- Beta (1Y)
- 0.48
- Revenue Growth
- -100.00%
- EPS Growth
- 238.88%
- Country
- US
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Oramed Pharm Business Overview & Revenue Model
Company Description
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypep...
Oramed Pharm Financial Statement Overview
Summary
A fortress balance sheet (86) is offset by weak income statement (38) and cash flow (41) scores. Equity of $339.1 million with just $1.5 million of debt gives Oramed a long runway and virtually no leverage risk. However, the company is still pre-commercial: revenue was zero in the trailing-twelve-month period, core operations lost roughly $12.1 million, and operating cash flow was negative $3.2 million. The headline net income of $154.8 million stems from non-operating, non-cash gains rather than the business itself, so earnings quality is low. The clear positive is the dramatic reduction in cash burn from $28.7 million in 2022 to low single-digit millions today.
Income Statement
38NegativeBalance Sheet
86Very PositiveCash Flow
41Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Sep 2023 | Dec 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 2.00M | 0 | 1.34M | 2.70M | 2.70M |
| Gross Profit | -91.00K | 13.00K | 0 | 1.34M | 2.70M | 2.70M |
| EBITDA | 151.83M | 75.44M | -14.87M | 7.32M | -40.54M | -24.15M |
| Net Income | 174.87M | 64.05M | -19.06M | 5.53M | -37.76M | -22.24M |
Balance Sheet | ||||||
| Total Assets | 369.64M | 230.86M | 155.28M | 220.55M | 161.64M | 128.00M |
| Cash, Cash Equivalents and Short-Term Investments | 50.61M | 125.89M | 141.93M | 162.05M | 155.72M | 94.14M |
| Total Debt | 733.00K | 825.00K | 372.00K | 51.62M | 894.00K | 533.00K |
| Total Liabilities | 52.17M | 31.12M | 9.93M | 57.66M | 10.49M | 11.48M |
| Stockholders Equity | 317.47M | 199.74M | 146.26M | 163.82M | 151.81M | 115.77M |
Cash Flow | ||||||
| Free Cash Flow | -5.01M | -11.08M | -8.43M | -10.55M | -29.20M | -21.56M |
| Operating Cash Flow | -5.21M | -9.14M | -8.41M | -10.29M | -28.70M | -21.18M |
| Investing Cash Flow | 21.50M | 5.44M | 105.82M | -73.04M | 30.21M | -22.26M |
| Financing Cash Flow | -16.68M | -4.74M | -52.04M | 51.98M | 11.56M | 101.39M |
Oramed Pharm Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Negative. The current price of 3.90 is below the 20-day moving average (MA) of 4.05, below the 50-day MA of 4.36, and below the 200-day MA of 4.06, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 34.41 is Neutral, neither overbought nor oversold. The STOCH value of 40.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORMP.
Oramed Pharm Risk Analysis
Oramed Pharm disclosed 42 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksOramed Pharm Peers Comparison
Overall Rating
ORMP54Neutral
SPRB47Neutral
ALXO40Underperform
WHWK40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | $169.60M | 1.12 | 52.95% | ― | -100.00% | 238.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $121.43M | -1.22 | -118.22% | ― | -100.00% | 58.95% | |
| 40Underperform | $138.28M | -1.16 | -73.35% | ― | ― | 48.20% | |
| 40Underperform | $177.62M | -2.75 | -55.66% | ― | -100.00% | -825.52% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ORMP | Oramed Pharmaceuticals Inc | 3.90 | 1.58 | 68.03% | |
| WHWK | Whitehawk Therapeutics, Inc. | 3.01 | 0.87 | 40.65% | |
| ALXO | Alx Oncology Holdings, Inc. | 1.00 | -0.63 | -38.65% | |
| SPRB | Spruce Biosciences, Inc. | 42.25 | -72.75 | -63.26% |
Oramed Pharm Corporate Events
Oramed Pharm Shareholders Back Governance and Incentive Plan
PositiveAt its Annual Meeting of Stockholders held on September 15, 2026, Oramed Pharm shareholders re-elected all incumbent directors to serve until the next annual meeting and ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
